

Abstract Code: FDI24887-80

COMPARISON OF HAS-BLED AND DOAC SCORE FOR BLEEDING RISK PREDICTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION TREATED WITH DIRECT ORAL ANTICOAGULANTS: A REAL-WORLD COHORT STUDY

A. Trovati¹, S. Ballestri¹, M. Bergamini¹, F. Zanni¹, B. Cuneo¹, L. Orlandi¹, M. Pasquinelli¹, M. Capitelli¹

(1) AUSL Modena, Pavullo nel Frignano, Italy.

Introduction. Bleeding risk assessment is recommended in patients with atrial fibrillation (AF) receiving oral anticoagulant therapy. HAS-BLED is the most commonly used score, but it was developed in vitamin K antagonist-treated populations and shows limited predictive ability. As direct oral anticoagulants (DOACs) are now first-line therapy in non-valvular AF, a DOAC-specific bleeding risk score was proposed in 2023, called “DOAC score”. This study aimed to compare the predictive accuracy of the two scores.

Materials and Methods. We conducted a retrospective observational study including patients with non-valvular AF treated with DOACs and followed at the Anticoagulation Center of Pavullo Hospital (AUSL Modena). HAS-BLED and DOAC scores were calculated. Predictive performance for major bleeding (MB) and for the combined endpoint of MB and clinically relevant non-major bleeding (CRNMB) was assessed using ROC curve analysis.

Results. The analysis included 228 patients (mean age 80.7 ± 8.6 years; 41.7% women). Major bleeding occurred in 16.2% of patients, while 25.0% experienced clinically significant bleeding. Both scores showed modest predictive ability for major bleeding (AUC 0.63 for DOAC score and 0.59 for HAS-BLED). The DOAC score demonstrated superior performance for both major bleeding and the combined endpoint of MB and CRNMB (AUC 0.66 vs 0.57; $p = 0.02$).

Conclusions. In a real-world cohort of patients with non-valvular AF treated with DOACs, the DOAC score outperformed HAS-BLED in predicting bleeding events, despite overall modest discrimination.